Switzerland-based Lonza and US-based Elusys have entered into an agreement to produce Anthim. Anthim is a therapeutic monoclonal antibody in late stage of development for the treatment of anthrax infection.
Anthim is an antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. Earlier, Anthim was granted Fast-Track status and Orphan Drug Designation by the FDA.
Under the agreement, Lonza will provide GS Gene Expression System for the process development services and manufacturing capacity for the product.
James Porter, Vice President of Development and Manufacturing at Elusys, said: “Elusys is pleased to initiate a partnership with Lonza for the production of Anthim. Lonza has considerable experience in large-scale manufacturing of monoclonal antibodies and a well-established reputation with regulatory agencies for the production of licensed products.